

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1.-62. (Cancelled).

63. (Currently Amended) An isolated human antibody or other antigen-specific binding molecule which specifically binds to a polypeptide comprising SEQ ID NO:2, wherein the antigen-specific binding molecule is selected from the group consisting of a single chain antibody, an Fab fragment, and an F(ab')₂ fragment.

~~selected from the group consisting of:~~

- ~~(a) SEQ ID NO:2; and~~
- ~~(b) a variant of SEQ ID NO:2 comprising a mutation selected from the group consisting of:~~
 - ~~(i) a conservative amino acid substitution in SEQ ID NO:2;~~
 - ~~(ii) an insertion of from 1-5 amino acids in SEQ ID NO:2; and~~
 - ~~(iii) a deletion of from 1-5 amino acids in SEQ ID NO:2;~~

~~wherein the polypeptide has chemotactic activity or activates neutrophils or monocytes.~~

64. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a neutralizing antibody.

65. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a polyclonal antibody.

66. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a monoclonal antibody.

67. (Previously Presented) A composition comprising the antibody or antigen-specific binding molecule of claim 63 and an acceptable excipient.

68. (Previously Presented) The composition of claim 67, wherein the antibody or antigen-specific binding molecule is labeled.

69. (Previously Presented) The composition of claim 67, wherein said label is selected from the group consisting of radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents and magnetic particles.

70.-71. (Cancelled).

72. (Previously Presented) The antibody of claim 66, wherein said antibody has an affinity of at least 10^8 M^{-1} .

73. (Previously Presented) The antibody of claim 72, wherein said antibody has an affinity of at least 10^9 M^{-1} .

74. (Previously Presented) The antibody of claim 73, wherein said antibody has an affinity of at least 10^{10} M^{-1} .

75.-77. (Cancelled).